Advanced searches left 3/3

Methotrexate Combination - Europe PMC

Summarized by Plex Scholar
Last Updated: 02 May 2022

* If you want to update the article please login/register

The Impact of Traditional Chinese Medicine QingreHuoxue Treatment and the Combination of Methotrexate and Hydroxychloroquine on the Radiological Progression of Active Rheumatoid Arthritis: A 52-Week Follow-Up of a Randomized Controlled Clinical Study.

Traditional Chinese medicine has been used to successfully treat rheumatoid arthritis. QingreHuoxue therapy is a Chinese medicine drug therapy for RA. To date, only few studies have compared the long-term effects of QRHXD with those of conventional disease-modifying antirheumatic drugs on RA disease function and radiological progression. There were no significant differences between the three groups: the traditional Chinese medicine comprehensive diagnostic clinic group, the Western medicine treatment group, and the integrated traditional Chinese and Western medicine treatment group. The disease activity index 28 of the three groups at 52 weeks was significantly lower than that at baseline, according to the ITT and PP data sets.

Source link: https://europepmc.org/article/MED/35463097


Quercetin and Methotrexate in Combination have Anticancer Activity in Osteosarcoma Cells and Repress Oncogenic MicroRNA-223.

Osteosarcoma is one of the most common bone neoplasms in adolescents. According to studies, OS chemotherapy regimens had no immediate short- and long-term adverse effects. Hence, new chemotherapeutic agents with the ability to potentiate OS chemotherapy products and shield non-tumorous tissue are therefore required. Methods Saos-2 cells were treated with Methotrexate and Quercetin alone and in combination, with Methotrexate and Quercetin single and in combination. Conclusions MTT's MTT findings showed that Que increases MTX cytotoxicity on OS cells. In the presence of Que, a decrease in MTX IC50 value was observed from 13. 7 ng/ml to 8. 45 ng/ml. In addition, the apoptosis rate in Saos-2 cells treated with a combination of MTX and Que soared from 6. 3 percent in the control group to 38. 3 percent. Conclusion Que, with the ability to raise the anticancer activity of MTX on Saos-2 cancer cells via proliferation inhibition and apoptosis induction, is a good candidate for combination therapy.

Source link: https://europepmc.org/article/MED/35385884


Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study.

Several observational studies showed that using ISDs in combination may be more effective than and as safe as monotherapy use. Methods and analysis The combining of THerapy, randomized, single-blinded study by a method III, multicentre, prospective, blind, and cost-effectiveness study of methotrexate, adalimumab, or their combination in non-infectious non-anterior uveitis is based on a longitudinal, multi-blinded study by the combining THerapy, mEtho We'll find patient subgroups with differing treatment responses by designing prediction models based on machine learning techniques using genetic and proteomic biomarkers in lieu of other secondary measures of efficacy and safety. The protocol, annexes, and informed consent forms were approved by the Reference Clinical Research Ethic Committee at the Hospital Clnico San Carlos and the Spanish Agency for Medicines and Health Products, which in turn approved the protocols, annexes, and information dissemination.

Source link: https://europepmc.org/article/MED/35318229


Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination.

Background To determine response to the methotrexate/etanercept combination in rheumatoid arthritis patients receiving the drug mixture in a well-documented cohort, we will use PROS and CO7 to forecast response to the methotrexate/etanercept combination in a well-documented cohort. Methods from the ESPOIR study, RA patients receiving the MTX/ETA or MTX/adalimumab combination as a first-line biologic therapy were also included in the ESPOIR cohort, RA patients undergoing the MTX/ETA or MTX/adalimumab combination as a first-line biologic therapy. Prior to the development of ETA or ADA, ELISA measured PROS and CO7 serum concentrations by ELISA during a time when the disease was present. Although there were no differences between demographic, pharma, epidemiological, bio, and X-rays findings, as well as CO7, serum PROS levels were consistently higher in responders to the MTX/ADA combination, although no difference was found in the group receiving MTX/ADA. Conclusion PROS may be one of a range of biomarkers capable of predicting the response of RTX/ETA combination in RA patients who are resistant to MTX.

Source link: https://europepmc.org/article/MED/35313956


Bioavailability, anti-inflammatory and anti-arthritic effect of Acetyl Keto Boswellic acid and its combination with methotrexate in an arthritic animal model.

Relevance of Rheumatoid arthritis is one of the most common disabling chronic autoimmune diseases affecting the adult population. Therefore, further study into Boswellia extract based on Acetyl Keto Boswellic Acid content, assuring its safety and security is also required. The synergistic effect of AKBA extract with methotrexate was also evaluated on an animal model. Methods and methods Oral bioavailability of 10% AKBA and the anti-inflammatory activity of 10% AKBA were determined and compared to 2% AKBA and diclofenac. In the FCA-induced arthritis animal model alone and combined with methotrexate at 2 mg/kg b. w. , the effect of 10% AKBA at 20 mg/kg and 40 mg/kg was investigated. From day 10 to day 45, Oral administration of 10% AKBA was carried out daily and MTX by intraperitoneal route, and MTX was administered by intraperitoneal route every week. AUC of AKBA increased AUC of AKBA by 10. 48 percent, 24. 22-fold, 47. 36 percent, and 110. 53-fold, compared to 2% AKBA at 40 mg/kg, 20 mg/kg, 20 mg/kg, and 40 mg/kg, respectively, as compared to 2% AKBA at 40 mg/kg, respectively. Perception paw edema inhibition of 10% AKBA at 20 mg/kg and 40 mg/kg were more than 10% average AKBA and diclofenac. Both doses of AKBA significantly reduced hepatic marker enzyme enzymes and total bilirubin levels at 10% AKBA. Conclusion Anti-inflammatory activity of AKBA due to lipoxygenase enzyme inhibition contributes to the use of AKBA in inflammatory disorders. A combination therapy of 10% AKBA with MTX is very effective in preventing arthritis and reducing hepatotoxicity caused by MTX in arthritic animals.

Source link: https://europepmc.org/article/MED/35306043


Search of official nationwide database in Japan for adverse events associated with disease-modifying antirheumatic drug therapies: focus on therapies in combination with methotrexate.

The number of each AE cases and its ratio to the total number of AEs cases were investigated. The combination of MTX was tested for RA cases. LPD was the most common among 3955 MTX cases. I-Pn was the most common in any of the other four DMARDs cases; PCP reports revealed the most common mixture MTX. MTX was used in 96 percent of PCP cases, 98. 2% of LPD and 97. 6% of PCP cases had MTX, and just over 2% of the other AEs cases had MTX, with less than 90% of the other AEs cases having MTX. Conclusion LPD was by far the most common AE associated with MTX therapy.

Source link: https://europepmc.org/article/MED/34762577


Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial.

This double-blind, placebo-controlled trial was conducted to determine the effectiveness and safety of Ld-IL2 in patients with active RA. All patients were given a stable dose of methotrexate. At week 24, the key results were the percentage of patients achieving the ACR20, DAS28-ESR 2. 6, and the change from baseline in CDAI or SDAI. The Ld-IL2 + MTX group's improvements were significantly higher across time points for the baseline in CDAI and SDAI studies than for the placebo+MTX group. At week 12 and week 24, more patients in the Ld-IL2+MTX group had ACR20 response in the Ld-MTX group than those in the placebo+MTX group. In addition, poor Treg and high IL-21 were both associated with positive responses to Ld-IL2 response. These findings revealed that Ld-IL2 was safe and healthy in RA.

Source link: https://europepmc.org/article/MED/35250032


Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy.

Patients with RA who had no or limited prior disease-modifying antirheumatic drug therapy were compared to baricitinib 4 mg, baricitinib 4 mg, and MTX in RA-BEGIN, a randomised, double-blind, phase 3 research. Patients with 30%, 50%, and 70 percent pain improvement from baseline were assessed over 52 weeks; a standardized questionnaire on health care; and time to achieve pain relief thresholds were assessed over 52 weeks; as were Patient Global Assessment and 36-Item Short Form Health Survey Physical Component Score findings. Baricitinib monotherapy or in combination with MTX provides faster pain relief than MTX alone over 52 weeks, according to Baricitinib monotherapy or a combination of MTX. Patients treated with MTX alone over a year were significantly faster and more pain relief, more weeks with limited to no pain, and more improvements in physical fitness after patients treated with MTX alone over a year.

Source link: https://europepmc.org/article/MED/35264432


Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).

Objectives Evaluation Objectives are used to evaluate the effectiveness and safety of the Janus kinase-1 inhibitor filgotinib in Japanese patients with rheumatoid arthritis and delayed responses to methotrexate. Proportions of patients with Disease Activity Score of 28 joints 2. 6 at Week 24 include filgotinib 200 mg, 56. 6 percent; adalimumab, 42. 9%; and placebo, 5. 3%; and placebo, 5. 3%. Conclusions Filgotinib once daily mixed with MTX was safe and well tolerated up to Week 24 in Japanese patients with RA and slow response to MTX.

Source link: https://europepmc.org/article/MED/34910188


Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).

Objects: To determine the efficacy and safety of filgotinib for Japanese patients with rheumatoid arthritis and limited or no prior methotrexate use. Patients with RA and limited or no prior MTX exposure were randomised in a 2:1:1:2 ratio to filgotinib 200 mg plus MTX, filgotinib 100 mg per MTX, filgotinib 200 mg, or MTX. Filgotinib was generally well tolerated among Japanese patients with RA and limited or no prior MTX use.

Source link: https://europepmc.org/article/MED/34910203

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions